drugset / Trial / NCT00833482

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

NCT00833482

Phase 1 Completed 185 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-label

Summary

This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The study also reviews the effects of atazanavir/ritonavir, 300/100 mg QD, on the pharmacokinetics of voriconazole, 200 mg, BID in healthy participants with functional CYP2C19 alleles.

Timeline

Start
2009-09
Primary completion
2010-07
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral
Comparator Voriconazole Small molecule 50 mg Oral
Comparator Voriconazole Small molecule 200 mg Oral